Navigation Links
Medicis in Medical News

BioMarin Announces Second Quarter 2009 Financial Results

... June 30, 2009, BioMarin had cash and short and long-term investments totaling $485.3 million. During the quarter, BioMarin made the final payment to medicis of $70.6 million related to the Orapred transaction. "During the quarter, we reported encouraging results from the Phase I PEG-PAL study, initi...

Dr. John L. LeRoy First Atlanta Plastic Surgeon to Perform Newly Approved Dysport Wrinkle Remover Injections for Facial Rejuvenation

... to use it. Dr. John L. LeRoy is helping Atlanta-area patients reduce the appearance of fine lines and wrinkles with the new Dysport®, licensed by medicis from French developer Ipsen. Dysport® functions much the same way as BOTOX® injections, and may now be considered one of its main competitors....

The Secrets to Staying Beautiful; Making the Most of Your Beauty Budget

...ylane ((R)) [Instructions for Use] Scottsdale, AZ: medicis Pharmaceutical Corporation; December 2008. ...rlane ((R)) [Instructions for Use] Scottsdale, AZ: medicis Pharmaceutical Corporation; February 2009. ...marks of HA North American Sales AB. (C) 2009 medicis Aesthetics Inc. RES 09-038A 06-30-10 ...

The Secrets to Staying Beautiful; Making the Most of Your Beauty Budget

...ylane ((R)) [Instructions for Use] Scottsdale, AZ: medicis Pharmaceutical Corporation; December 2008. ...rlane ((R)) [Instructions for Use] Scottsdale, AZ: medicis Pharmaceutical Corporation; February 2009. ...marks of HA North American Sales AB. (C) 2009 medicis Aesthetics Inc. RES 09-038A 06-30-10 ...

New Survey Reveals High Expectations for Popular Aesthetic Injections

...linum Toxin Survey NewsWorthy Analysis. February--March 2009. Data on file, medicis Pharmaceutical Corporation. 2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March 2009. Data on file, medicis Pharmaceutical Corporation. Important Safety Information Dysport...

Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort

...d effective, Hydrelle is also a financially attractive alternative to traditional fillers such as Juvederm(R) by Allergan Medical, and Restylane(R) by medicis Pharmaceutical. Hydrelle has been specifically formulated to deliver rapid results comparable to other hyaluronic acid fillers; and the lidocaine...

Hyperion Therapeutics Raises $60 Million Series C

...ent of therapies that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 in August 2007. Under the terms of the agreement, Hyperion is conductin...

Joseph E. Whitters Joins MyoScience, Inc. Board of Directors

...ns in aesthetics. Major investors in MyoScience, include De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures, and medicis Capital GmbH. Press Contacts: Robert M. Curtis, President and CEO MyoScience, Inc. bcurtis@myoscience.com (650) 474-2600...

Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis

...ent of therapies that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 in August 2007. Under the terms of the agreement, Hyperion is conductin...

New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble

...omote the Dysport(TM) brand as part of a U.S. sales agreement with the manufacturer, Ipsen. Adding Dysport(TM) to their dermal filler empire positions medicis as a formidable foe to Allergan and their arsenal of beauty treatments (Botox(R) and the Juvederm(R) hyaluronic acid gel fillers). Botox(R) by Al...
Medicis in Medical Technology

Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders

...al unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 in August 2007. Under the terms of the agreement, Hyperion is conductin...

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders

...enal excretion of phenylacetylglutamine, which is formed from phenylacetic acid and glutamine. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 in August 2007. Under the terms of the agreement, Hyperion is conducti...

RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial

... RADIESSE(R) is a registered trademark of BioForm Medical, Inc. Restylane(R) is a registered trademark of HA North American Sales AB, a subsidiary of medicis Pharmaceutical Corporation. Contact: Adam Gridley 650.286.4025 Vice President, Corporate Development BioForm Medical, Inc. ...
Medicis in Biological Technology

DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania

...e soft-tissue volume loss, thus returning the dermis to its original youthful state. Current marketed fillers include market-leader Restylane, sold by medicis Pharmaceutical, and Radiesse sold by Bioform. "We were very pleased to be selected for an investment by Ben Franklin Technology Partners as a part o...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...SI ) Imclone Systems (Nasdaq: IMCL ) Inverness Medical Innovations (Amex: IMA ) Invitrogen Corp. (Nasdaq: IVGN ) Medarex Inc. (Nasdaq: MEDX ) medicis Pharmaceutical (NYSE: MRX ) Mentor Corp. (NYSE: MNT ) ONYX Pharmaceuticals Inc. (Nasdaq: ONXX ) PDL BioPharma, Inc. (Nasdaq: PDLI ) Pharmion C...

BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results

...demarks of BioMarin Pharmaceutical Inc. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Orapred(R) is a registered trademark of medicis Pediatrics, Inc. and is used under license. Contact: Investors Media Eugenia Shen ...

Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event

...s commitments and capitalize on the opportunity presented by our recently announced strategic collaboration with Ucyclyd Pharma, Inc., a subsidiary of medicis Pharmaceutical Corporation," said Chris Rivera, President and CEO. "This team brings a unique and proven track record of developing, gaining regulator...

Hyperion Therapeutics Secures $40 Million In Series B Round

...confidence in Hyperion and our team," said Chris Rivera, President and CEO of Hyperion. "The funding will allow us to complete the licensing deal with medicis Pharmaceutical Corporation (see press release dated August 28, 2007), build out our management team, advance our clinical trials in UCD and HE, and be...

BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco

... trademarks of BioMarin Pharmaceutical Inc. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Orapred(R) is a registered trademark of medicis Pediatrics, Inc. and is used under license. Contact: Investors Media Eugenia Shen ...
Other Tags
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... entry featured by the Huffington Post on August 25th, writer Akela Stanfield detailed ... bariatric surgery. While the author acknowledged that she had always seen herself as someone ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... swamped with a large stream of mixed documents that include EOBs, payments, and ... documents, while extracting the data needed to reconcile their billing, with one efficient ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Sciences clinical and academic partnership has earned international recognition as a premier center ... disorder that can cause sudden, catastrophic internal bleeding and stroke. , Cure ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
Breaking Medicine News(10 mins):Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2
(Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
Other Contents